tirzepatide and sertraline Wellbutrin tirzepatide: can you take them together safely? Navigating Weight Loss and Mental

Some interesting data for obesity and emerging for MASH Many thanks to Ahmad Bahareth, MD for sharing Mazdutide: One of the Most Exciting Obesity Therapies to Watch in 2026 By Innovent Biologics Mazdutide (GLP-1/GCG dual receptor agonist) continues to build momentum with impressive clinical and regulatory achievements, positioning itself as a major competitor in the obesity and metabolic disease landscape

How it works: Activates both GIP and GLP-1 receptors Even stronger appetite suppression than semaglutide Better insulin sensitivity improvements May increase energy expenditure more than semaglutide alone Possibly better muscle mass preservation during weight loss The dual mechanism is why it outperforms semaglutide

Choi JY, Neuhouser ML, Barnett M, Hudson M, Kristal AR, Thornquist M, King IB, Goodman GE, Ambrosone CB

Here is the important part: every gram of glycogen binds approximately 3 grams of water

These programs can be especially helpful for uninsured or underinsured patients